Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/legend-biotech-corp">Legend Biotech Corp</a>oration (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating profitability (15% operating margin, $33.25 million net income), driven by global CARVYKTI net trade sales surging 50% year-over-year to approximately $657 million.</li>
  <li>Commercial expansion of CARVYKTI (ciltacabtagene autoleucel), co-developed and commercialized under a 50/50 worldwide profit-split with Johnson &amp; Johnson, continues to strengthen via label expansion into 2nd-to-4th line multiple myeloma (CARTITUDE-4) and unparalleled long-term durability data (CARTITUDE-2 5-year progression-free survival rate of 50%).</li>
  <li>At a last price of $19.04, Legend trades at an attractive enterprise value to sales multiple of ~2.4x annualized run-rate revenue, backed by $965 million in cash and short-term investments, providing an asymmetric risk-reward profile as the market discounts recent CEO leadership succession and pipeline execution toward in vivo CAR-T (LB2501).</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Legend Biotech Corporation (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating profitability (15% operating margin, $33.25 million net income), driven by global CARVYKTI net trade sales surging 50% year-over-year to approximately $657 million.
  Commercial expansion of CARVYKTI (ciltacabtagene autoleucel), co-developed and commercialized under a 50/50 worldwide profit-split with Johnson &amp; Johnson, continues to strengthen via label expansion into 2nd-to-4th line multiple myeloma (CARTITUDE-4) and unparalleled long-term durability data (CARTITUDE-2 5-year progression-free survival rate of 50%).
  At a last price of $19.04, Legend trades at an attractive enterprise value to sales multiple of ~2.4x annualized run-rate revenue, backed by $965 million in cash and short-term investments, providing an asymmetric risk-reward profile as the market discounts recent CEO leadership succession and pipeline execution toward in vivo CAR-T (LB2501).
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Legend Biotech Corp (LEGN US) - Oct 2026

China

Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Legend Biotech Corp (LEGN US) - Oct 2026

Legend Biotech Corporation (NASDAQ: LEGN) reached a historic financial inflection point in Q2 2026 by achieving company-wide GAAP operating...

αSK Primers